* This is a professional Version *
Hypophosphatemia is serum phosphate (PO 4 ) concentration < 2.5 mg/dL (0.81 mmol/L). Causes include alcoholism, burns, starvation, and diuretic use. Clinical features include muscle weakness, respiratory failure, and heart failure; seizures and coma can occur. Diagnosis is by serum PO 4 concentration. Treatment consists of PO 4 supplementation.
Hypophosphatemia occurs in 2% of hospitalized patients but is more prevalent in certain populations (eg, it occurs in up to 10% of hospitalized patients with alcoholism).
Hypophosphatemia has numerous causes, but clinically significant acute hypophosphatemia occurs in relatively few clinical settings, including the following:
Acute severe hypophosphatemia with serum PO 4 < 1 mg/dL (< 0.32 mmol/L) is most often caused by transcellular shifts of PO 4 , often superimposed on chronic PO 4 depletion.
Chronic hypophosphatemia usually is the result of decreased renal PO 4 reabsorption. Causes include the following:
Severe chronic hypophosphatemia usually results from a prolonged negative PO 4 balance. Causes include
Ingestion of aluminum is particularly prone to cause PO 4 depletion when combined with decreased dietary intake and dialysis losses of PO 4 in patients with end-stage renal disease.
Although hypophosphatemia usually is asymptomatic, anorexia, muscle weakness, and osteomalacia can occur in severe chronic depletion. Serious neuromuscular disturbances may occur, including progressive encephalopathy, seizures, coma, and death. The muscle weakness of profound hypophosphatemia may be accompanied by rhabdomyolysis, especially in acute alcoholism. Hematologic disturbances of profound hypophosphatemia include hemolytic anemia, decreased release of O 2 from Hb, and impaired leukocyte and platelet function.
Hypophosphatemia is diagnosed by a serum PO 4 concentration < 2.5 mg/dL (< 0.81 mmol/L). Most causes of hypophosphatemia (eg, diabetic ketoacidosis, burns, refeeding) are readily apparent. Testing to diagnose the cause is done when clinically indicated (eg, suggestive liver function test results or signs of cirrhosis in patients with suspected alcoholism).
Treatment of the underlying disorder and oral PO 4 replacement are usually adequate in asymptomatic patients, even when the serum concentration is very low. PO 4 can be given in doses up to about 1 g po tid in tablets containing Na or K PO 4 . Oral Na or K PO 4 may be poorly tolerated because of diarrhea. Ingestion of 1 L of low-fat or skim milk provides 1 g of PO 4 and may be more acceptable. Removal of the cause of hypophosphatemia may include stopping PO 4 binding antacids or diuretics or correcting hypomagnesemia.
Parenteral PO 4 is usually given IV. It should be administered in any of the following circumstances:
IV administration of KPO 4 (as buffered mix of K 2 HPO 4 and KH 2 PO 4 ) is relatively safe when renal function is well preserved. NaPO 4 (rather than KPO 4 ) preparations generally should be used in patients with impaired renal function. The usual parenteral dose of KPO 4 is 2.5 mg (0.08 mmol)/kg IV over 6 h. Patients with alcoholism may require ≥ 1 g/day during TPN; supplemental PO 4 is stopped when oral intake is resumed. Serum Ca and PO 4 concentrations should be monitored during therapy, particularly when PO 4 is given IV or to patients with impaired renal function. In most cases, no more than 7 mg/kg (about 500 mg for a 70-kg adult) of PO 4 should be given over 6 h. Close monitoring is done and more rapid rates of PO 4 administration should be avoided to prevent hypocalcemia, hyperphosphatemia, and metastatic calcification due to excessive Ca× PO 4 product.
Acute hypophosphatemia most often is caused by alcoholism, burns, or starvation.
Chronic hypophosphatemia may be due to hormonal disorders (eg, hyperparathyroidism, Cushing syndrome, hypothyroidism), chronic diuretic use, or use of aluminum-containing antacids by patients with chronic kidney disease.
Hypophosphatemia is usually asymptomatic, but severe depletion can cause anorexia, muscle weakness, and osteomalacia.
Treat the underlying disorder, but some patients require oral, or rarely, IV phosphate replacement.
Drug NameSelect Trade
* This is a professional Version *